Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 18;16(1):75.
doi: 10.1186/s13045-023-01457-x.

Clinical development of mRNA therapies against solid tumors

Dawei Wu #  1 , Lingfeng Hu #  2 , Xin Wang #  1   3 , Yue Yu #  1 , Shuo-Peng Jia  1   4 , Hui-Yao Huang  1 , Zi-Wei Li  1   5 , Jin-Feng Ma  3 , Hai-Bo Zhu  3 , Yu Tang  1 , Ning Li  6
Affiliations

Clinical development of mRNA therapies against solid tumors

Dawei Wu et al. J Hematol Oncol. .

Abstract

The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated that the clinical development of mRNA therapies against solid tumors is still at an early stage. There are evolutions in delivery systems from the dendritic cell to the lipid-based platform and in encoding strategies from the fixed tumor antigens to the personalized neoantigens. The adjuvant or maintenance therapy and the combination treatment with checkpoint inhibitors are becoming the major clinical development orientation.

Keywords: Clinical trial; Delivery system; Messenger RNA; Solid tumor; Tumor antigen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Annual numbers of newly tested mRNA therapeutics by delivery system
See this image and copyright information in PMC

References

    1. Beck JD, Reidenbach D, Salomon N, et al. mRNA therapeutics in cancer immunotherapy. Mol Cancer. 2021;20(1):69. doi: 10.1186/s12943-021-01348-0. - DOI - PMC - PubMed
    1. Lorentzen CL, Haanen JB, Met Ö, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450–e458. doi: 10.1016/S1470-2045(22)00372-2. - DOI - PMC - PubMed
    1. Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. doi: 10.1186/s12943-021-01335-5. - DOI - PMC - PubMed
    1. https://pharmaintelligence.informa.com/products-and-services/data-and-an.... Accessed March 8, 2023
    1. Xu S, Yang K, Li R, et al. mRNA vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582. doi: 10.3390/ijms21186582. - DOI - PMC - PubMed

Publication types